Sunitinib Versus Placebo for Patients with Advanced Unresectable Pancreatic Neuroendocrine Tumors
0 Mga view
• 07/09/23
0
0
I-embed
administrator
Mga subscriber
From ASCO 2011 -- A discussion with Prof. Eric Raymond on his poster presented at ASCO in June 2011 titled "Updated Overall Survival (OS) and Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) of Sunitinib Versus Placebo for Patients with Advanced Unresectable Pancreatic Neuroendocrine Tumors (NET)"
Magpakita ng higit pa
Mga Komento sa Facebook
SORT BY-
Mga Nangungunang Komento
-
Pinakabagong komento